

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4554461

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
TIBOR KELER	08/08/2017
THOMAS DAVIS	08/08/2017
RECEIVING PARTY DATA	
Name:	CELLEX THERAPEUTICS, INC.
Street Address:	53 FRONTAGE ROAD
Internal Address:	SUITE 220
City:	HAMPTON
State/Country:	NEW JERSEY
Postal Code:	08827
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	15384205
Application Number:	15613192
CORRESPONDENCE DATA	
Fax Number:	(202)371-2540
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2023712600
Email:	ckim@skgf.com, bdudley@skgf.com, pduffy@skgf.com, mforrest@skgf.com
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX PLLC
Address Line 1:	1100 NEW YORK AVENUE, NW
Address Line 4:	WASHINGTON, D.C. 20005
ATTORNEY DOCKET NUMBER:	3338.0450002/ELE/C-K/BMD
NAME OF SUBMITTER:	JI-EUN KIM
SIGNATURE:	/Ji-Eun Kim, Reg. No. 68,504/
DATE SIGNED:	08/17/2017
Total Attachments: 2	
source=3338.0450002 - Assignment#page1.tif	
source=3338.0450002 - Assignment#page2.tif	

ASSIGNMENT

We,

Tibor KELER and Thomas DAVIS,

pursuant to contractual obligations heretofore assumed by us and/or for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell and assign to **Celldex Therapeutics, Inc.**, a Delaware corporation, having a place of business at 53 Frontage Road, Suite 220, Hampton, NJ 08827, its successors, assigns and legal representatives, all our right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to us by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention entitled:


**USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH
ANTI-CD27 ANTIBODY IN CANCER TREATMENT**


invented by us and described in the United States non-provisional patent application

**Application Number 15/384,205, filed December 19, 2016 and
Application Number 15/613,192, filed June 03, 2017**

including said United States non-provisional patent application and any application claiming priority from said United States non-provisional patent application, filed in any country, and any patents which may be issued and/or granted thereon, and all divisions, continuations, reissues, reexamination certificates and extensions thereof in all countries, the said interest being the entire ownership of said invention and all of said applications, patents (including reissue patents), extensions and reexamination certificates to be held and enjoyed by Celldex Therapeutics, Inc. and its successors and assigns to the full end of the terms to which said patents (including reissue patents), extensions and reexamination certificates may be granted and/or issued, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made;

And We hereby agree to communicate to said Assignee or its representatives any facts known to us respecting said invention, to testify in any legal proceedings, to sign and/or execute any further documents and/or instruments which may be necessary, lawful and proper in and/or for the filing and/or prosecution of all applications, including divisional, continuation and reissue applications, extensions and reexamination certificates and/or the granting and/or issuance thereof and/or to otherwise secure title to said invention and all of said applications, patents (including reissue patents, extensions and reexamination certificates in said assignee, and in general to do everything possible to aid said assignee, its successors and assigns to obtain and enforce proper protection for said invention in all countries).

Signed this 8th day of August, 2017 by 
Tibor KELER

Signed this 8th day of August, 2017 by 
Thomas DAVIS

5368116_1.docx